EHP-101

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

VCE-004.8 是 PPARγ 和 CB2 受体的特异性双重激动剂，具有有效的抗炎活性。 VCE-004.8 减弱脂肪生成并预防饮食引起的肥胖。

VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.(In Vivo):In HFD mice, VCE-004.8 (injection; 20?mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) .

——

Etrinabdione (i.p.; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. Etrinabdione can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels.

VCE-004.8

GPCR/G Protein

Cannabinoid Receptor

——

——

——

1818428-24-8

433.592

C28H35NO3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (115.32 mM)

CCCCCC1=C(NCc2ccccc2)C(=O)C([C@@H]2C=C(C)CC[C@H]2C(C)=C)=C(O)C1=O

——

(-20℃)

With Ice Pack

≥ 2 years